This activity has expired. Credit is no longer available.
This activity is supported by independent educational grants from AstraZeneca and Bristol-Myers Squibb.

Metastatic Urothelial Carcinoma

Laura J. Zitella, MS, RN, ACNP-BC, AOCN®
Stanford Health Center

After decades of no new approvals for the treatment of metastatic urothelial cancer, a malignancy associated with a low survival rate, novel immunotherapeutic agents are changing the treatment landscape for bladder cancer. Learn about the therapies showing activity in this malignancy and get clinical pearls on how to manage a patient with urothelial cancer with immune-related hepatitis and pancreatitis.



 
 

Download Slides


 
These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo

in collaboration with

JADPRO CE Logo APSHO Logo
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.